Close
Digital Health & Ai Innovation summit 2026
Medical Taiwan 2026

NeuroGeneration Recruits Top Scientist To Direct New Division of Biotherapeutics and Drug Discovery

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media PackNow

– Book a Conference Call

Leave Message for Us to Get Back

Related stories

ARPA-H Launches IGoR Program for AI...

The Advanced Research Projects Agency for Health has officially...

Medline Launches AI-Powered Supply Chain Platform...

Medline Industries has unveiled a new artificial intelligence-driven supply...

DOJ Launches West Coast Strike Force...

The United States Department of Justice has launched a...
senior research neuroscientist from The Salk Institute, Mohamedi Kagalwala PhD, has been recruited to head NeuroGeneration's new laboratories in La Jolla, California. Dr. Kagalwala, an expert on neural stem cells, will become director of the new Division of Biotherapeutics and Drug Discovery.
 
"I am extremely pleased to lead NeuroGeneration's new Division and expand its technology of adult neural stem cells for Parkinson's disease. It will allow us to develop personalized iPS cell therapies for degenerative brain disorders," said Dr. Kagalwala. "In addition, by investigating intrinsic neurogenesis and brain repair mechanisms, our team will be able to modify discrete molecular mechanisms during aging and neurodegenerative changes. We will then be in a better position to influence the environment, either with drugs or cellular therapies, to prevent the progression of disease and facilitate brain repair."
 
This new Division will complement the neural stem cell therapy studies for Parkinson's disease and other Atypical Parkinsonism led by Dr. Michel Levesque, NeuroGeneration's scientific founder.
 
Within the new facility providing core state of the art technologies, NeuroGeneration will expand its bioinformatic platforms to include personalized neurogenomic, analysis for drug target discovery for aging, Parkinson's disease, Stroke, Amyotrophic Lateral Sclerosis, Alzheimer's disease, Multiple Sclerosis, Epilepsy, Depression and Schizophrenia.
 
ABOUT NEUROGENERATION:
 
NeuroGeneration is a life science company designing new cellular therapies and biological modulators for the prevention and treatment of neurodegenerative disorders. The company has completed a Phase I clinical trial for Parkinson's disease using adult-derived autologous neural stem cells. It intends to complete a Phase II study for the treatment of Parkinson's disease as soon as it receives final approval from the FDA. NeuroGeneration's Division of Biotherapeutics and Drug Discovery offers molecular products using its drug discovery platforms to target neuroprotective and endogenous repair mechanisms.
MEDICAL FAIR ASIA 2026
MEDICAL FAIR CHINA

Latest stories

Related stories

ARPA-H Launches IGoR Program for AI in Biomedical Research

The Advanced Research Projects Agency for Health has officially...

Medline Launches AI-Powered Supply Chain Platform in Partnership with Microsoft

Medline Industries has unveiled a new artificial intelligence-driven supply...

AI Emergency Triage Study Shows Superior Clinical Accuracy

A Harvard-led study has found that advanced artificial intelligence...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Translate »